AVIR
Atea Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
4.11
close · 2026-10-30
value
31
cheaper than peers31
quality
81
stronger fundamentals81
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.61× | 65 |
| earnings yield, 3 years ago | -33.8% | 57 |
| earnings yield, 2 years ago | -39.7% | 52 |
| earnings yield, 1 year ago | -48.7% | 40 |
| cash flow yield, 2 years ago | -25.9% | 37 |
| earnings yield, latest year | -47.2% | 33 |
| cash flow yield, 1 year ago | -41.1% | 30 |
| cash flow yield, latest year | -40.1% | 28 |
| cash flow yield, 3 years ago | -37.3% | 28 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.3% | 91 |
| return on equity | -52.6% | 57 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $330M |
| free cash flow | -$87.7M |
| employees | 55 |
| first trade | 2020-10-30 |
| next earnings | 2026-08-12 |
| fundamentals updated | 2026-08-12 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.94 | -2.00 | -1.63 | -1.39 |
| free cash flow | -$132.0M | -$135.5M | -$85.4M | -$122.9M |
| net income | -$158.3M | -$168.4M | -$136.0M | -$115.9M |
| revenue | $0 | $0 | $0 | $0 |